- Home
- GH vs NOVT Comparison
GH vs NOVT Comparison
Compare GH & NOVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- NOVT
- Stock Information
- Founded
- GH 2011
- NOVT 1968
- Country
- GH United States
- NOVT United States
- Employees
- GH N/A
- NOVT N/A
- Industry
- GH Medical Specialities
- NOVT Industrial Machinery/Components
- Sector
- GH Health Care
- NOVT Miscellaneous
- Exchange
- GH Nasdaq
- NOVT Nasdaq
- Market Cap
- GH 6.1B
- NOVT 5.1B
- IPO Year
- GH 2018
- NOVT N/A
- Fundamental
- Price
- GH $40.64
- NOVT $134.47
- Analyst Decision
- GH Strong Buy
- NOVT Hold
- Analyst Count
- GH 20
- NOVT 1
- Target Price
- GH $48.40
- NOVT $160.00
- AVG Volume (30 Days)
- GH 2.6M
- NOVT 287.1K
- Earning Date
- GH 05-08-2025
- NOVT 05-06-2025
- Dividend Yield
- GH N/A
- NOVT N/A
- EPS Growth
- GH N/A
- NOVT N/A
- EPS
- GH N/A
- NOVT 1.77
- Revenue
- GH $739,016,000.00
- NOVT $949,245,000.00
- Revenue This Year
- GH $19.11
- NOVT $7.24
- Revenue Next Year
- GH $21.44
- NOVT $7.07
- P/E Ratio
- GH N/A
- NOVT $75.18
- Revenue Growth
- GH 31.04
- NOVT 7.67
- 52 Week Low
- GH $15.81
- NOVT $133.17
- 52 Week High
- GH $50.89
- NOVT $187.12
- Technical
- Relative Strength Index (RSI)
- GH 46.62
- NOVT 33.83
- Support Level
- GH $34.88
- NOVT $136.02
- Resistance Level
- GH $45.00
- NOVT $144.08
- Average True Range (ATR)
- GH 3.11
- NOVT 4.70
- MACD
- GH -0.28
- NOVT -0.72
- Stochastic Oscillator
- GH 51.89
- NOVT 6.49
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About NOVT Novanta Inc.
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.